ATE553098T1 - Verfahren zur herstellung von rosuvastatin- calcium - Google Patents
Verfahren zur herstellung von rosuvastatin- calciumInfo
- Publication number
- ATE553098T1 ATE553098T1 AT08702369T AT08702369T ATE553098T1 AT E553098 T1 ATE553098 T1 AT E553098T1 AT 08702369 T AT08702369 T AT 08702369T AT 08702369 T AT08702369 T AT 08702369T AT E553098 T1 ATE553098 T1 AT E553098T1
- Authority
- AT
- Austria
- Prior art keywords
- rosuvastatin calcium
- producing rosuvastatin
- producing
- calcium
- dihydroxyhept
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 229960004796 rosuvastatin calcium Drugs 0.000 title 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 title 1
- AVDMILNVMOXCHF-DHMAKVBVSA-N calcium;(e,3r,5s)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound [Ca].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O AVDMILNVMOXCHF-DHMAKVBVSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN277CH2007 | 2007-02-08 | ||
| IN1121CH2007 | 2007-05-29 | ||
| PCT/IB2008/000290 WO2008096257A1 (en) | 2007-02-08 | 2008-02-04 | An improved process for preparation of rosuvastatin calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE553098T1 true ATE553098T1 (de) | 2012-04-15 |
Family
ID=39323006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08702369T ATE553098T1 (de) | 2007-02-08 | 2008-02-04 | Verfahren zur herstellung von rosuvastatin- calcium |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8212035B2 (de) |
| EP (1) | EP2125754B1 (de) |
| AT (1) | ATE553098T1 (de) |
| AU (1) | AU2008212622B2 (de) |
| CA (1) | CA2677809A1 (de) |
| ES (1) | ES2385623T3 (de) |
| WO (1) | WO2008096257A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6835838B2 (en) * | 2002-01-28 | 2004-12-28 | Novartis Ag | Process for the manufacture of organic compounds |
| US7851624B2 (en) | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
| KR20090018964A (ko) | 2007-04-18 | 2009-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | Ｈｍｇ-ｃｏａ 환원 효소 억제제의 중간체의 제조 방법 |
| WO2010071595A1 (en) * | 2008-12-19 | 2010-06-24 | Sekab Biofuels & Chemicals Ab | Denaturant-containing, ethanol-based liquid |
| US9701642B2 (en) * | 2013-08-30 | 2017-07-11 | Nissan Chemical Industries, Ltd. | Method for producing optically active 5-hydroxy-3-ketoester |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| GB9903472D0 (en) | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
| US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| GB0204129D0 (en) | 2002-02-21 | 2002-04-10 | Novartis Ag | Process for the manufacture of organic compounds |
| EA200401533A1 (ru) | 2002-05-21 | 2005-06-30 | Ранбакси Лабораторис Лимитед | Способ получения росувастатина |
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| US7566782B2 (en) | 2002-12-10 | 2009-07-28 | Ranbaxy Laboratories Limited | Process for the preparation of rosuvastatin |
| US7396927B2 (en) | 2003-08-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| EP1678148A1 (de) | 2003-10-22 | 2006-07-12 | Ranbaxy Laboratories Limited | Verfahren zur herstellung von amorphen rosuvastatin-calcium |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| WO2005051921A1 (en) | 2003-11-24 | 2005-06-09 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| WO2006035277A2 (en) | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium |
| TWI345562B (en) | 2005-02-22 | 2011-07-21 | Teva Pharma | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof |
| US20070167625A1 (en) | 2005-02-22 | 2007-07-19 | Anna Balanov | Preparation of rosuvastatin |
| US20070037979A1 (en) | 2005-02-22 | 2007-02-15 | Valerie Niddam-Hildesheim | Preparation of rosuvastatin |
| US20090124803A1 (en) | 2005-03-22 | 2009-05-14 | Pandurang Balwant Deshpande | Process for preparation of rosuvastatin |
| WO2006106526A1 (en) * | 2005-04-04 | 2006-10-12 | Unichem Laboratories Limited | Process for preparation of calcium salt of rosuvastatin |
| EP2508514B1 (de) | 2005-06-24 | 2017-10-18 | LEK Pharmaceuticals d.d. | Verfahren zur Herstellung von amorphem Rosuvastatincalcium frei von Verunreinigungen |
| ES2564807T5 (es) | 2005-06-24 | 2019-02-26 | Lek Pharmaceuticals | Proceso para preparación de rosuvastatina de calcio amorfa pura |
| CZ299215B6 (cs) | 2005-06-29 | 2008-05-21 | Zentiva, A. S. | Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny |
| GB0514078D0 (en) | 2005-07-08 | 2005-08-17 | Astrazeneca Uk Ltd | Chemical process |
| WO2007017117A1 (en) | 2005-07-28 | 2007-02-15 | Lek Pharmaceuticals D.D. | Process for the synthesis of rosuvastatin calcium |
| EP1919880A2 (de) | 2005-08-16 | 2008-05-14 | Teva Pharmaceutical Industries Ltd. | Rosuvastatincalcium mit geringem gehalt an salzhaltigen nebenprodukten |
| TW200804305A (en) | 2005-10-03 | 2008-01-16 | Teva Pharma | Diastereomeric purification of rosuvastatin |
| WO2007099561A1 (en) | 2006-02-27 | 2007-09-07 | Cadila Healthcare Limited | Process for preparing rosuvastatin calcium |
| US8404841B2 (en) | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
| EP2022784A1 (de) | 2007-08-08 | 2009-02-11 | LEK Pharmaceuticals D.D. | Verfahren zur Herstellung des Methylesters von Rosuvastatin |
| HU230637B1 (hu) | 2007-10-12 | 2017-05-29 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Eljárás rosuvastatin intermedierek előállítására |
-
2008
- 2008-02-04 US US12/449,426 patent/US8212035B2/en not_active Expired - Fee Related
- 2008-02-04 WO PCT/IB2008/000290 patent/WO2008096257A1/en not_active Ceased
- 2008-02-04 CA CA002677809A patent/CA2677809A1/en not_active Abandoned
- 2008-02-04 EP EP08702369A patent/EP2125754B1/de not_active Not-in-force
- 2008-02-04 AU AU2008212622A patent/AU2008212622B2/en not_active Ceased
- 2008-02-04 ES ES08702369T patent/ES2385623T3/es active Active
- 2008-02-04 AT AT08702369T patent/ATE553098T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2385623T3 (es) | 2012-07-27 |
| US20090312547A1 (en) | 2009-12-17 |
| EP2125754A1 (de) | 2009-12-02 |
| AU2008212622B2 (en) | 2011-01-27 |
| EP2125754B1 (de) | 2012-04-11 |
| US8212035B2 (en) | 2012-07-03 |
| AU2008212622A1 (en) | 2008-08-14 |
| WO2008096257A1 (en) | 2008-08-14 |
| CA2677809A1 (en) | 2008-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI341310B (en) | Improved production of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid calcium salt | |
| MY142615A (en) | Crystalline form of bis [ (e)-7-4(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r, 5s)-3,5-dihydroxyhept-6 -enoic acid] calcium salt | |
| IS8478A (is) | Aðferð til að framleiða kalsíumsalt rósúvatatín (E)-7-[4-(4-flúorfenýl)-6-ísóprópýl-2-[metýl(metýlsúlfónýl)amínó]pýrimídín-5-ýl] (3R,5S)-3,5-díhýdroxýhept-6-enósýru og kristölluð milliefni þess | |
| WO2009157014A3 (en) | A process for preparing hmg-coa reductase inhibitors and intermediates | |
| JOP20190231B1 (ar) | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به | |
| EE05288B1 (et) | 7-[4-(4-fluorofenl)-6-isopropl-2-metl(metlsulfonl)amino]primidiin-5-l] -(3R,5S)-3,5- dihdrokshept-6-enohappe kristalsed soolad | |
| DK1144389T3 (da) | Krystallinsk bis(E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-ensyre]calciumsalt | |
| EA201070410A1 (ru) | Твердые формы (s)-этил-2-амино-3-(4-(2-амино-6-((r)-1-(4-хлор-2-(3-метил-1h-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата и способы их применения | |
| ATE501126T1 (de) | Verfahren zur herstellung von rosuvastatin | |
| MY180039A (en) | N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator | |
| DE602007008691D1 (de) | Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind | |
| UA112423C2 (uk) | Спосіб одержання (варіанти) кристалічних форм розувастатину тба | |
| DE602004004679D1 (de) | Verfahren zur herstellung des hemicalciumsalzes von (e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-ämethyl(methylsulfonyl)aminoüpyrimidin-5-ylü(3r,5s)-3,5-dihydroxy-6-heptensäure | |
| NZ611072A (en) | Method for preparing rosuvastatin salts | |
| MX2010011006A (es) | Nueva sal de un derivado de pirimidina. | |
| TR200800269A2 (tr) | Stabil farmasötik formülasyon ve hazırlama yöntemleri | |
| AR043594A1 (es) | Un procedimiento para la preparacion de la sal de calcio del acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-[metil(metil-sulfonil)amino]pirimidin-5-il] (3r,5s)-3,5-dihidroxihept-6-enoico y compuesto utilizable en dicho procedimiento |